Early experience optimizing immunosuppressive use and monitoring in MyPEAK-1, a first-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy
9 May 2026 (15:55 - 16:04)
Organised by: 
About the speaker
Cleveland Clinic, Cleveland (United States of America)
6 More presentations in this session
Doctor A. Aimo (Pisa, IT)
Access the full session
The Event
Heart Failure 2026
9 May 2026
15:55 CET
You may be interested in
Congress Session
Congress Session
Congress Presentation
